Compare $FTH vs $MDXG | Chartloom

Compare

$FTH vs $MDXG

Faeth Therapeutics, Inc · MiMedx Group Inc

FTH

Faeth Therapeutics, Inc

MDXG

MiMedx Group Inc

Compare $FTH vs $MDXG

Comparing Faeth Therapeutics, Inc and MiMedx Group Inc

FTHFaeth Therapeutics, Inc

MDXGMiMedx Group Inc

FTHFaeth Therapeutics, Inc

Market cap

$671M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

79.1%

52W performance

79.1%

FCF yield

-5.0%

MDXGMiMedx Group Inc

Market cap

$681M

P/E (TTM)

110.63x

Forward P/E (NTM)

130.81x

Forward P/S (NTM)

2.16x

Rev growth (TTM)

-2.4%

YTD performance

-27.9%

52W performance

-34.2%

FCF yield

6.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FTH

MDXG

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

MDXG

MiMedx Group Inc

Market Cap

FTH$671M

MDXG$681M

Enterprise Value

FTH$644M

MDXG$562M

Price

FTH$26.03

MDXG$4.67

P/E Ratio

FTHN/A

MDXG110.63x

P/S Ratio

FTH0.00x

MDXG1.92x

EV/Sales

FTH0.00x

MDXG1.58x

EV/EBITDA

FTH0.00x

MDXG27.54x

P/B Ratio

FTH4.08x

MDXG3.10x

P/FCF Ratio

FTHN/A

MDXG15.32x

EV/FCF

FTH-19.02x

MDXG12.65x

PEG Ratio

FTHN/A

MDXGN/A

Forward P/E (NTM)

FTHN/A

MDXG130.81x

Forward P/S (NTM)

FTHN/A

MDXG2.16x

Revenue (TTM)

FTH$0

MDXG$355M

Revenue Growth (YoY)

FTHN/A

MDXG-2.4%

Forward Rev Growth

FTH77.6%

MDXG22.1%

Gross Margin (TTM)

FTH0.0%

MDXG78.8%

Operating Margin (TTM)

FTH0.0%

MDXG2.5%

EBITDA Margin (TTM)

FTH0.0%

MDXG5.7%

Net Margin (TTM)

FTH0.0%

MDXG1.8%

FCF Margin (TTM)

FTHN/A

MDXG12.5%

Net Income (TTM)

FTH$-196M

MDXG$6M

FCF (TTM)

FTH$-34M

MDXG$44M

EPS (TTM)

FTH-$34.65

MDXG$0.04

ROE (TTM)

FTH-18959.0%

MDXG2.6%

ROA (TTM)

FTH-17568.0%

MDXG2.0%

ROIC (TTM)

FTH-18946.0%

MDXG2.4%

Cash

FTH$27M

MDXG$136M

Debt

FTH$0

MDXG$17M

Net Cash/Debt

FTH$27M

MDXG$119M

Current Ratio (TTM)

FTH19.69x

MDXG5.33x

Quick Ratio (TTM)

FTH19.55x

MDXG4.79x

Debt/Equity (TTM)

FTH0.00x

MDXG0.08x

Debt/Assets (TTM)

FTH0.0%

MDXG0.0%

Interest Coverage (TTM)

FTHN/A

MDXGN/A

Net Debt/EBITDA (TTM)

FTH0.00x

MDXG0.00x

Beta

FTH2.05

MDXG1.20

52W Performance

FTH79.1%

MDXG-34.2%

YTD Performance

FTH79.1%

MDXG-27.9%

% from 52W High

FTH-38.2%

MDXG-41.4%

% from 52W Low

FTH93.8%

MDXG54.1%

Asset Turnover (TTM)

FTH0.00x

MDXG1.14x

FCF Yield (TTM)

FTH-5.0%

MDXG6.5%

Earnings Yield (TTM)

FTH-29.1%

MDXG0.9%

Dividend Yield (TTM)

FTHN/A

MDXGN/A

Rule of 40

FTH0.0

MDXG10.1

EV/GP/RG

FTHN/A

MDXG0.09

Ticker research

View FTH research View MDXG research

Metric	FTH Faeth Therapeutics, Inc	MDXG MiMedx Group Inc
Market & Valuation
Market Cap	$671M	$681M
Enterprise Value	$644M	$562M
Price	$26.03	$4.67
P/E Ratio	N/A	110.63x
P/S Ratio	0.00x	1.92x
EV/Sales	0.00x	1.58x
EV/EBITDA	0.00x	27.54x
P/B Ratio	4.08x	3.10x
P/FCF Ratio	N/A	15.32x
EV/FCF	-19.02x	12.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	130.81x
Forward P/S (NTM)	N/A	2.16x
Revenue & Growth
Revenue (TTM)	$0	$355M
Revenue Growth (YoY)	N/A	-2.4%
Forward Rev Growth	77.6%	22.1%
Profitability
Gross Margin (TTM)	0.0%	78.8%
Operating Margin (TTM)	0.0%	2.5%
EBITDA Margin (TTM)	0.0%	5.7%
Net Margin (TTM)	0.0%	1.8%
FCF Margin (TTM)	N/A	12.5%
Net Income (TTM)	$-196M	$6M
FCF (TTM)	$-34M	$44M
EPS (TTM)	-$34.65	$0.04
ROE (TTM)	-18959.0%	2.6%
ROA (TTM)	-17568.0%	2.0%
ROIC (TTM)	-18946.0%	2.4%
Financial Health
Cash	$27M	$136M
Debt	$0	$17M
Net Cash/Debt	$27M	$119M
Current Ratio (TTM)	19.69x	5.33x
Quick Ratio (TTM)	19.55x	4.79x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	1.20
52W Performance	79.1%	-34.2%
YTD Performance	79.1%	-27.9%
% from 52W High	-38.2%	-41.4%
% from 52W Low	93.8%	54.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.14x
FCF Yield (TTM)	-5.0%	6.5%
Earnings Yield (TTM)	-29.1%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	10.1
EV/GP/RG	N/A	0.09
Ticker research	View FTH research	View MDXG research

Valuation

P/E Ratio

MDXG

110.63x

P/S Ratio

FTH

0.00x

MDXG

1.92x

EV/FCF

FTH

-19.02x

MDXG

12.65x

Growth & revenue

Revenue Growth TTM

MDXG

-2.4%

Forward Revenue Growth

FTH

77.6%

MDXG

22.1%

Profitability & performance

Gross Margin

MDXG

78.8%

FTH

0.0%

ROE

MDXG

2.6%

FTH

-18959.0%

FCF Yield %

MDXG

6.5%

FTH

-5.0%

52-Week Performance

FTH

79.1%

MDXG

-34.2%

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

MDXG

MiMedx Group Inc

Market Cap

FTH$671M

MDXG$681M

Enterprise Value

FTH$644M

MDXG$562M

Price

FTH$26.03

MDXG$4.67

P/E Ratio

FTHN/A

MDXG110.63x

P/S Ratio

FTH0.00x

MDXG1.92x

EV/Sales

FTH0.00x

MDXG1.58x

EV/EBITDA

FTH0.00x

MDXG27.54x

P/B Ratio

FTH4.08x

MDXG3.10x

P/FCF Ratio

FTHN/A

MDXG15.32x

EV/FCF

FTH-19.02x

MDXG12.65x

PEG Ratio

FTHN/A

MDXGN/A

Forward P/E (NTM)

FTHN/A

MDXG130.81x

Forward P/S (NTM)

FTHN/A

MDXG2.16x

Revenue (TTM)

FTH$0

MDXG$355M

Revenue Growth (YoY)

FTHN/A

MDXG-2.4%

Forward Rev Growth

FTH77.6%

MDXG22.1%

Gross Margin (TTM)

FTH0.0%

MDXG78.8%

Operating Margin (TTM)

FTH0.0%

MDXG2.5%

EBITDA Margin (TTM)

FTH0.0%

MDXG5.7%

Net Margin (TTM)

FTH0.0%

MDXG1.8%

FCF Margin (TTM)

FTHN/A

MDXG12.5%

Net Income (TTM)

FTH$-196M

MDXG$6M

FCF (TTM)

FTH$-34M

MDXG$44M

EPS (TTM)

FTH-$34.65

MDXG$0.04

ROE (TTM)

FTH-18959.0%

MDXG2.6%

ROA (TTM)

FTH-17568.0%

MDXG2.0%

ROIC (TTM)

FTH-18946.0%

MDXG2.4%

Cash

FTH$27M

MDXG$136M

Debt

FTH$0

MDXG$17M

Net Cash/Debt

FTH$27M

MDXG$119M

Current Ratio (TTM)

FTH19.69x

MDXG5.33x

Quick Ratio (TTM)

FTH19.55x

MDXG4.79x

Debt/Equity (TTM)

FTH0.00x

MDXG0.08x

Debt/Assets (TTM)

FTH0.0%

MDXG0.0%

Interest Coverage (TTM)

FTHN/A

MDXGN/A

Net Debt/EBITDA (TTM)

FTH0.00x

MDXG0.00x

Beta

FTH2.05

MDXG1.20

52W Performance

FTH79.1%

MDXG-34.2%

YTD Performance

FTH79.1%

MDXG-27.9%

% from 52W High

FTH-38.2%

MDXG-41.4%

% from 52W Low

FTH93.8%

MDXG54.1%

Asset Turnover (TTM)

FTH0.00x

MDXG1.14x

FCF Yield (TTM)

FTH-5.0%

MDXG6.5%

Earnings Yield (TTM)

FTH-29.1%

MDXG0.9%

Dividend Yield (TTM)

FTHN/A

MDXGN/A

Rule of 40

FTH0.0

MDXG10.1

EV/GP/RG

FTHN/A

MDXG0.09

Ticker research

View FTH research View MDXG research

Metric	FTH Faeth Therapeutics, Inc	MDXG MiMedx Group Inc
Market & Valuation
Market Cap	$671M	$681M
Enterprise Value	$644M	$562M
Price	$26.03	$4.67
P/E Ratio	N/A	110.63x
P/S Ratio	0.00x	1.92x
EV/Sales	0.00x	1.58x
EV/EBITDA	0.00x	27.54x
P/B Ratio	4.08x	3.10x
P/FCF Ratio	N/A	15.32x
EV/FCF	-19.02x	12.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	130.81x
Forward P/S (NTM)	N/A	2.16x
Revenue & Growth
Revenue (TTM)	$0	$355M
Revenue Growth (YoY)	N/A	-2.4%
Forward Rev Growth	77.6%	22.1%
Profitability
Gross Margin (TTM)	0.0%	78.8%
Operating Margin (TTM)	0.0%	2.5%
EBITDA Margin (TTM)	0.0%	5.7%
Net Margin (TTM)	0.0%	1.8%
FCF Margin (TTM)	N/A	12.5%
Net Income (TTM)	$-196M	$6M
FCF (TTM)	$-34M	$44M
EPS (TTM)	-$34.65	$0.04
ROE (TTM)	-18959.0%	2.6%
ROA (TTM)	-17568.0%	2.0%
ROIC (TTM)	-18946.0%	2.4%
Financial Health
Cash	$27M	$136M
Debt	$0	$17M
Net Cash/Debt	$27M	$119M
Current Ratio (TTM)	19.69x	5.33x
Quick Ratio (TTM)	19.55x	4.79x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	1.20
52W Performance	79.1%	-34.2%
YTD Performance	79.1%	-27.9%
% from 52W High	-38.2%	-41.4%
% from 52W Low	93.8%	54.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.14x
FCF Yield (TTM)	-5.0%	6.5%
Earnings Yield (TTM)	-29.1%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	10.1
EV/GP/RG	N/A	0.09
Ticker research	View FTH research	View MDXG research